



A Comprehensive Review in Parenteral Formulations

Heyam Saad Ali*

Professor, Department of Pharmaceutics, Faculty of Pharmacy, University of Khartoum, Sudan

***Corresponding Author:** Heyam Saad Ali, Professor, Department of Pharmaceutics, Faculty of Pharmacy, University of Khartoum, Sudan.

Received: December 24, 2018

Published: June 30, 2020

© All rights are reserved by **Heyam Saad Ali.**

Abstract

Parenteral Formulations are sterile, pyrogen-free, administered by injection through skin layers. This review highlights all the aspects regarding parenteral products advantages, disadvantages, routes of administration, additives, preparation, types of containers and quality control tests for evaluation.

Keywords: Parenteral Formulations; Antimicrobial Agents; Needle

Introduction

Parenteral Formulations have both advantages and disadvantages.

Advantages

- Provide rapid clinical response in emergency cases such as epilepsy, asthma. Cardiac and hypertensive crisis (especially IV route).
- It is an alternative route for find it hard to swallow e.g. unconscious or nauseous patients.
- Certain parenteral products can provide prolonged drug action, e.g. benzathine penicillin-G can provide a prolonged action of up to a month when given I.M.

Disadvantages

- Difficulty of removal of the drug from the body in case of intoxication.
- Local irritation as a result of needle insertion.
- High cost of production.
- Unappropriated administration.

Routes of administration of parenteral products

- Intradermal route (I.D.).
- Subcutaneous route (S.C.).

- Intramuscular route (I.M.).
- Intravenous route (I.V.).

Intradermal route

It is superficial injection into skin layers. (between the epidermis and dermis) into the anterior surface of the forearm.

Uses

- For diagnostic tests, e.g., test for susceptibility to certain bacterial diseases such as tuberculosis and diphtheria.
- Administration of BCG vaccine (used for immunization against tuberculosis). Volume given: about 0.1 ml.

Subcutaneous route

The drug is injected into the subcutaneous tissues beneath the dermis, usually into the upper arm or thigh or the lower part of the abdomen. Volume: not more than 1 ml because of limited S.C. area. However, sometimes larger volumes can be given if hyaluronidase enzyme (available as injection) is co-formulated with the drug. The enzyme will break down hyaluronic acid which holds the S.C. cells together and the S.C surface area will be increased. Thus more drug will spread allowing accommodation of more volume of injection.

Drug absorption from S.C. area is rapid compared the I.D. area because: (a) larger S.C. surface area (b) richer vascular supply of S.C. area.

Examples of drugs given by S.C. route

- All insulin preparations.
- Some vaccines such as rabies and cholera vaccines.

Intramuscular route

The drug is injected deeply into the skeletal muscle of the upper arm or the gluteal muscle of the buttocks.

Advantages over I.D. and S.C.

- Highly vascular and larger surface area, therefore 2 - 5 ml in upper arm and 5 ml in gluteal muscle.
- Suitable for aqueous, oily solutions and aqueous suspension.

Examples

- Oily solutions of drugs: Depo-testosterone (containing testosterone propionate dissolved in sesame oil)
- Aqueous suspensions of drugs such as Depo-medrol (containing methylprednisolone suspended in water). The two preparations are slowly-dissolving formulations if injected I.M. and thus provide prolonged action.
- Vaccines: Cholera, diphtheria, influenza, are given I.M.

Intravenous route

Used for large or small volumes of drug solution. Vein mostly used: the median basilic vein of the inner forearm.

- **Advantages:** Rapid drug action, therefore used in emergency cases.
- **Disadvantages:** Drug cannot be recovered in cases of poisoning.

Form of drug given:

- Most drugs given I.V. are aqueous solutions.
- Emulsions of very fine droplets, e.g. phytonadione (vit-K used as anticoagulant to stop hemorrhage).
- Volume: Up to 1000 ml by slow I.V., in replacement therapy: Ringers solution containing NaCl, KCl and CaCl₂), Dextrose-NaCl I.V. solution.

General procedure for the preparation of parenteral products

Parenteral products must be free from particulate matter and microorganisms; therefore room of preparation must be free from dust and microorganisms. This is achieved as follows:

- Fitting laminar air flow system to suck dust and microorganisms; uv radiation will kill microorganisms.
- Room walls and benches cleaned by antimicrobial agents.
- Workers should wear sterilized clothes and disinfected gloves and masks to protect their mouths and noses and wear plastic glasses to protect their eyes from uv lamps.

Steps involved in the preparation of parenteral products

- Cleaning and sterilizing all equipment and containers. Cleaning: using automatic washing and rinsing machines.
- **Sterilization:** Dry or moist heat.
- **Purity of ingredients:** drugs, vehicles, additives. For water as solvent use water for injection.
- **Compounding of the preparation:** Add small quantity first then larger to form solution.
- **Filtration:** Use millipore membrane composed of cellulose acetate filters, for thermo-labile solutions; removes microorganisms.
- **Distribution of preparation into final containers:** Bottles, ampoules, plastic bags. Glass preferred since it high temperature during sterilization. Amber colored glass used for photolabile drugs but this interferes with visual inspection for foreign material.
- Closing and sealing of containers.
- **Sterilization:** Of filled and closed containers.
- Visual inspection for clarity.
- **Labeling:** Name and quantity of ingredients, storage conditions, manufacturing and expiry dates.

Sterilization of parenteral products

Sterilization: Is the process of killing or removing of all living microorganisms from a certain preparation or material. Most essential methods are:

- Dry heat.
- Moist heat or steam.
- Filtration.

Quality control (or evaluation) of parenteral preparations

The following tests are done to ensure that the parenteral products meet the required standards of safety and effectiveness:

- Sterility test
- Clarity test
- Pyrogen test
- Leaker test.

Sterility test

All Parenteral products should be sterile. Sterility test is performed on randomly selected samples.

Principle of the test

A quantity of the material is transferred to a suitable liquid culture medium contained in a tube. A number of culture media are used:

- Thioglycolate liquid medium: used to support the growth of anaerobic organisms. It is incubated for 7 days at 35 - 37°C.
- Soybean-casein liquid medium: to support the growth of aerobic organisms. It is incubated for 7 days at 35 - 37°C.
- Sabaraud liquid medium to support the growth of fungi, incubated at 25 - 27°C.

Positive controls for 10 days:

- A thioglycolate liquid medium is cultured with the bacterium *Clostridium sporogenes* which is anaerobic, incubated for 7 days at 35 - 37°C.
- Soybean-casein liquid medium is cultured with aerobic Staph. Aureus to confirm the fertility of the medium; incubated at 35 - 37°C for 7 days.
- Sabaraud liquid medium is cultured with the fungus *Candida albicans* to confirm fertility of the medium; incubated at 25 - 27°C for 10 days.

Negative controls

The three culture media containing no microorganisms and no sample are also incubated at the specified temperature and times as negative controls to confirm the sterility of the media. If the sample contains antimicrobial agent then it must be inactivated by dilution or by addition of a specific inactivator, e.g., phenyl mercuric nitrate is inactivated by thioglycolic acid.

Observations of the sterility test

The tested material is sterile if no growth or turbidity in a, b, c, g, while d, e, f, show growth. If growth observed in a, b, c, g, or no growth in d, e, f, the test should be repeated with fresh sample. If there is growth repeat test. If still there is growth then preparation is unsterile and is rejected.

Pyrogen test

Pyrogens are metabolic products which are produced by all microorganisms from their cell wall. They consist of liposaccharide and they are water soluble, filterable and thermostable. They are not removed after sterilization by moist heat or filtration. In the human body they cause febrile reaction (fever, headache, backache). Major source of pyrogens is water which is used as a vehicle. Pyrogens can be removed by adding oxidizing agent (potassium permanganate + small quantity of barium) to oxidize pyrogens to nonvolatile organic solids (filterable).

Pyrogen test

It is performed on all aqueous parenteral preparations. Rabbits are used for the test since they show same response to pyrogens as humans.

Principle of the test: Measuring the rise in temperature (fever) caused by pyrogens, using a thermometer placed in the rectum of the rabbit.

The sample (10 ml/kg) is injected into the ear vein of 8 rabbits. The temperature is recorded before injecting and the after injecting at 1, 2, and 3 hours. The rectal temperature should not exceed 0.6°C from normal recorded temperature.

Recently: *In vitro* pyrogen testing.

Principle: The test solution is added to a lysate solution. If pyrogens are present a gel will be formed; if pyrogens are not present the solution remains clear. The method is more sensitive and rapid than the *in vivo* testing (in rabbits).

Clarity test

Clarity is defined as the freedom of parenteral preparations from any foreign matter. The clarity of solutions is visually inspected under strong light.

Leaker test

This test is specific for ampoules to test that they are effectively sealed with no leak.

Steps:

- The ampoules are immersed in a tank containing dye solution (1% methylene blue).
- The tank is closed and the air inside is evacuated to form negative pressure inside the tank. The vacuum will create high pressure on the weak points on the ampoule seal and will also assist the passage of the dye into the leaking ampoule.
- The ampoules are washed and any leaking one will contain the blue dye and should be rejected.

Added substances (or Additives)

Additives or excipients are the substances which are added for the following reasons:

- To maintain the solubility of the drug.
- To maintain the stability of the drug.
- To maintain the sterility of the product.
- To maintain the isotonicity of the product.
- To ease the administration of the product.

Additives used to maintain the solubility of the drug

To enhance the solubility of poorly water-soluble drugs, one of the following procedures can be adopted.

The addition of one or more water miscible solvents to the hydrophobic drug.

Examples of the water miscible solvents:

- Polyethylene glycol (PEG).
- Propylene glycol (PG).
- Glycerol and ethanol.

Complex formation

The addition of certain complexing agents to drugs to enhance water solubility.

Example

Sodium benzoate is used to solubilize caffeine by forming a highly water-soluble complex.

The addition of surface active agents and suspending agents

Example of surface active agents:

- Tweens
- Spans

Uses of surface active agents

- To enhance the solubility of certain oil soluble drugs, e.g., vitamins (A, D, E, and K).
- To enhance the wettability and promote the dispersion of solids in the solvent of parenteral suspensions.
- To prevent the formation of foams.

Examples of suspending agents

- Sodium carboxy methyl cellulose.
- Methyl cellulose.
- Polyvinyl pyrrolidone.
- They are used to reduce the sedimentation rate of the suspended particles in parenteral suspensions.
- They should not be used in high concentration to avoid the increase in the viscosity of the injected suspension.

Additives used to maintain the stability of the drug

It is important to protect such drugs from:

- Hydrolysis
- Oxidation

Drug can be protected from hydrolysis by:

- Preparation of the drug in the form of dry solid powder to be reconstituted with a suitable vehicle at the time of administration.
- Preparation of the drug as an insoluble suspension.
- Partial or total replacement of water with other Nonaqueous solvents (PG, PEG ...).
- Adjusting the pH of the formulation to the pH of maximum stability by using buffers.

Drugs can be protected against oxidation by one or more of the following procedures:

The addition of antioxidants:

- Water-soluble antioxidants.
- Oil-soluble antioxidants.

The displacement of oxygen with other inert gases (N, CO₂), used for single dose injections.

Addition of chelating agents (EDTA, citric acid ...) to complex with divalent or trivalent ions (Fe²⁺, Fe³⁺, Cu²⁺, Cu³⁺ or Mg²⁺), which are present as traces in water, to inhibit oxidation.

Additives used to maintain the sterility of the product

Antimicrobial agents or preservatives are added to multiple dose containers to prevent the growth of microorganisms.

Properties of antimicrobial agents used

- Compatible with other ingredients used.
- Non-toxic. Non-irritant and inert.
- Should not be absorbed by rubber or plastic closure.
- Should be thermostable.

Examples of preservatives used

- Quaternary ammonium compounds.
- Phenyl mercuric nitrate.
- Phenol, cresol and chlorobutanol.
- Benzyl alcohol.
- A combination of methyl parabens and propyl parabens.

Additives used to maintain the isotonicity of Parenteral products

Parenteral solutions should be isotonic with blood plasma.

- Hypotonic solutions cause hemolysis of RBCs.
- Hypertonic solutions cause shrinkage of RBCs.

Additives used to ease the administration of parenteral products

Examples

- Local anesthetics (procaine, xylocaine ...) are used in I.M. injections (tetracycline, keflin injections) to reduce the pain.
- Hydrocortisone and heparin are added to amphotericin-B I.M. injection in order to reduce inflammation and pain and to enhance blood flow so as to increase drug absorption.

Vehicles used in parenteral preparations

Aqueous vehicles

Water: Is the most commonly used vehicle for parenteral preparations and is the most suitable since aqueous preparations are well tolerated by the body and are the safest to be used.

Different types of water used include:

- Water for injection.
- Sterile water for injection.
- Bacteriostatic water for injection.

Nonaqueous vehicles

- Water-miscible vehicles.
- Water-immiscible vehicles

Water for injection

It is obtained by de-ionizing and distilling water. It should contain no more than 1 mg/100 ml of total solids. It must be pyrogen-free but it is not required to be sterile.

Sterile water for injection

It is water for injection which has been sterilized and packaged in single dose containers having a volume not exceeding 1 litre. It is pyrogen-free and does not contain an antimicrobial agent. For example: an injectable solution may be prepared from dry powder of sterile Ampicillin sodium by adding sterile water for injection [1-26].

Bacteriostatic water for injection

It is sterile water for injection where antimicrobial agents are added. It is packaged in multiple dose containers to allow the repetitive withdrawal of water from container without exposure to bacterial contamination.

Volume not more 5 ml since bacteriostatic agents are toxic if used in large concentration.

Incompatibilities of bacteriostatic water for injection

Examples

- When bacteriostatic water for injection containing benzyl alcohol is used to suspend sterile chloramphenicol for I.M. injection, the suspension formed is found to be very viscous and very difficult to withdraw from container. However, chloramphenicol sodium succinate does not interact with benzyl alcohol and forms a clear solution.
- Certain acidic drugs, such as barbiturates and sulphonamides, are incompatible with parabens which are used as bacteriostatic agents.

Multiple dose units or injections

- They usually contain a number of doses (up to 10 doses) in the same container.

- The container is made of borosilicate glass and is known as vial. The vials are fitted or closed with rubber closure to allow the penetration of the needle without the destruction of the rubber closure.
- The closure should reseal after the withdrawal of the needle in order to protect the vial contents from contamination.
- The total volume of such multiple dose injection does not exceed 30 ml.

Examples

- Vitamin B-complex injection.
- Insulin injection.

Non-aqueous vehicles

Aqueous vehicles are preferred for parenteral preparations but it is sometimes necessary to eliminate water from certain preparations for one of the following reasons:

- To enhance the solubility of certain poorly water soluble drugs by replacing water with other non-aqueous vehicles.
- To protect certain drugs from hydrolytic reactions.

Properties of non-aqueous vehicles used in parenteral preparations:

- Nontoxic, non-irritant and inert.
- Stable and compatible with other ingredients used.
- Should have suitable viscosity to be easily withdrawn from the container and easily injected.

Non-aqueous vehicles used in parenteral preparations include:

- Water miscible vehicles.
- Water immiscible vehicles.

Water miscible vehicles

These are used to:

- Enhance drug stability.
- Enhance drug solubility.

The most commonly used water miscible vehicles include:

- Polyethylene glycol (PEG).
- Propylene glycol (PG)
- Ethanol

Examples of some injections containing water miscible vehicles:

- Digoxin (cardiotonic), I.M. and I.V.
- Diazepam (sedative, hypnotic), I.M., I.V.
- Phenytoin sodium (antiepileptic), I.M., I.V.

Water immiscible vehicles

These include fixed vegetable oil such as sesame oil, peanut, and cotton seed oil.

- Because of it is the most stable, sesame oil is the vehicle most commonly used.
- Mineral oils such as paraffin oil are not used as vehicles since they are not absorbed by the body tissues.

The main uses of oils as vehicles are to

- Solubilize hydrophobic or oily drugs.
- Protect water sensitive drugs.
- Obtain a prolonged or sustained release action.

These drugs:

- Should be highly soluble in oil.
- Are slowly released from oily vehicles.
- Should never be administered I.V.
- Should be administered only I.M.

Fixed oil**Some examples of drugs formulated in fixed oil:**

- Dimercaprol injection: dissolved in peanut oil (used as antidote for heavy metal poisoning: arsenic, mercury and gold).
- Testosterone propionate: dissolved in sesame oil or cotton seed oil (used to treat testosterone deficiency).
- Fluphenazine decanoate: dissolved in sesame oil, (used to control schizophrenia, tranquilizer).

All the above injections are given I.M.

Parenteral suspensions

These are Parenteral products composed of a drug suspended in a suitable vehicle.

Parenteral suspensions are applied in two forms:

- Suspension ready for injection.
- Dry insoluble solid products, which can be reconstituted with a suitable vehicle at the time of administration.

Some examples of the first form of suspension include:

- **Insulin-semilente:** A suspension of zinc-amorphous insulin complex used in the treatment of insulin-dependent diabetes mellitus; duration of action: 12 - 16 hr.
- **Insulin-ultralene:** A suspension of zinc-crystalline insulin complex; duration of action 36 hr.
- **Insulin-lente:** A suspension containing zinc-amorphous.

Insulin and zinc-crystalline insulin complex; duration of action 24 hr.

Some examples of the second form of suspension include:

- Sterile methyl prednisolone acetate suspension (Depo-Medrol).
- Sterile hydrocortisone acetate suspension.
- Sterile chloramphenicol for suspension (Chloromycetin).
- Sterile benzathine-penicillin G for suspension (Penadur LA).
- All the above are suspended in sterile water for injection to produce an aqueous suspension.
- Parenteral suspensions should not be administered by I.V. since the insoluble particles may block the capillaries.

Parenteral suspensions give slow or sustained release of drugs since the dissolve slowly.

Formulation of parenteral products

Several components are used in parenteral preparations.

The active ingredients include:

- The vehicle.
- The active ingredient

In order to formulate a stable, effective and safe parenteral preparation, all ingredients used, including drug, should be evaluated for their purities, solubility, and compatibilities with each other.

In formulating parenteral preparations, a suitable vehicle for dissolving the drug has to be used.

Parenteral emulsions

- Few drugs are formulated as Parenteral emulsions, mainly as O/W emulsions.
- It is necessary to achieve stable very fine emulsion droplets to prevent aggregation in the blood vessels which may promote the aggregation of platelets resulting in thrombophlebitis.

Examples

- Intralipid I.V emulsions.
- Oil soluble vitamins (A, E and D) I.M. injection.
- Phytomenadione (vit. K) I.V. injection.

Bibliography

1. Remington, the Science and Practice of Pharmacy, Parenteral Preparation, 20th edition. Philadelphia: ISE publication 1 (2000).
2. Ford JL. "Parenteral products". In: Aulton ME, (ed.) *Pharmaceutics: The Science of Dosage Form Design*. New York; Longman (1988).
3. Ansel HC., *et al.* "Pharmaceutical dosage forms and drug delivery system, 7th edition". Lippincott Williams and Wilkins: Philadelphia (1999).
4. Colombo G., *et al.* "Stabilized aqueous suspensions for parenteral use". US6495534 (2002).
5. Beecher P. "Encyclopedia of emulsion technology, basic theory". Marcel Dekker: New York 1 (1983).
6. Collins Gold LC., *et al.* "Parenteral emulsions for drug delivery". *Advanced Drug Delivery Reviews* 5 (1990): 189-208.
7. Singh M and Ravin L. "Parenteral emulsions as drug carrier systems". *Journal of Parenteral Science and Technology* 40 (1986): 34-44.
8. Brazeau GA., *et al.* "Dosage Forms: Parenterals". In: Swarbrick James (Ed.). *Encyclopedia of Pharmaceutical Technology*. 3rd edition. Informa Healthcare USA, Inc: New York 1 (2007): 1001-1011.
9. The United States Pharmacopeia, the National Formulary. US Pharmacopeial Convention, Rockville, MD (1995): 1775-1777.
10. Groves MJ. "Parenteral drug delivery system". In: Mathiowitz Edith (Ed.). *Encyclopedia of Controlled Release*. John Wiley and Sons, Inc: New York 1-2 (1952): 743-777.
11. Chien YW. "Parenteral drug delivery and delivery systems". In: *Novel drug delivery system*, 2nd ed. 50. Marcel Dekker: New York (1992): 382-385.
12. Avis KE., *et al.* "Pharmaceutical dosage forms: Parenteral medications". Marcel Dekker: New York 1992; 1.
13. JC Boylan and AL Fites. *Parenteral Products*, in *Modern Pharmaceutics*, G.L. Banker and C.T. Rhodes, Eds. (Marcel Dekker Inc., New York, NY), (1979): 445.
14. PP DeLuca and JC Boylan. *Formulation of Small-Volume Parenterals in Pharmaceutical Dosage Forms: Parenteral Medications*, K.E. Avis *et al.*, Eds. (Marcel Dekker Inc., New York, NY), (1992): 215.
15. RJ Harwood., *et al.* "The Processing of Small-Volume Parenterals and Related Sterile Products" in *Pharmaceutical Dosage Forms: Parenteral Medications 2* (1993): 61.
16. Gadzag M., *et al.* "Stable parenteral compositions of vinblastine or vincristine". US5397784 (1995).
17. Brahmkankar DM and Jaiswal SB. "Absorption of drugs". In: *Biopharmaceutics and pharmacokinetics a treatise*. Vallabh Prakashan: Delhi (2006).

18. Patel RM. "Parenteral suspension: An overview". *International Journal of Current Pharmaceutical Research* 2.3 (2010): 4-13.
19. Chang HC., *et al.* "Parenteral sustained release dosage forms of butorphanol for dogs". *International Journal of Current Pharmaceutical Research* 176 (1999): 147-56.
20. KE Avis., *et al.* *Forms: Parenteral Medications*. Eds. (Marcel Dekker Inc., New York, NY) (1993): 61.
21. The United States Pharmacopeia, the National Formulary. US Pharmacopoeial Convention, Rockville, MD, 1995; 1775-7. Encyclopedia of Controlled Release. John Wiley and Sons, Inc: New York 1-2 (1952): 743-77.
22. Singh M and Ravin L. "Parenteral emulsions as drug carrier systems". *Journal of Parenteral Science and technology* 40 (1986): 34-44.
23. Date AA., *et al.* "Parenteral microemulsions: An overview". *International Journal of Pharmaceutics* 355 (2008): 19-30.
24. JK Haleblian. "Characterization of Habits and Crystalline Modifications of Solids and Their Pharmaceutical Applications". *Journal of Pharmaceutical Sciences* 64.8 (1975): 1269-1288.
25. S Byrn., *et al.* "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations". *Pharmaceutical Research* 12.7 (1995): 945-954.
26. K Ashizawa., *et al.* "Solid-State Stability and Preformulation Study of a New Parenteral Cephalosporin Antibiotic (E1040)". *Yakugaku Zasshi* 110.3 (1990): 191-201.

Assets from publication with us

- Prompt Acknowledgement after receiving the article
- Thorough Double blinded peer review
- Rapid Publication
- Issue of Publication Certificate
- High visibility of your Published work

Website: www.actascientific.com/

Submit Article: www.actascientific.com/submission.php

Email us: editor@actascientific.com

Contact us: +91 9182824667